| Literature DB >> 35740216 |
Md Mahbubur Rashid1,2, Zubair Akhtar1,3, Sukanta Chowdhury1, Md Ariful Islam1, Shahana Parveen1, Probir Kumar Ghosh1, Aninda Rahman4, Zobaidul Haque Khan5, Khaleda Islam5, Nitish Debnath5, Mahmudur Rahman6, Fahmida Chowdhury1.
Abstract
For supporting antibiotic stewardship interventions, the World Health Organization (WHO) classified antibiotics through the AWaRe (Access, Watch, and Reserve) classification. Inappropriate use of antimicrobials among hospital-admitted patients exposes them to the vulnerability of developing resistant organisms which are difficult to treat. We aimed to describe the proportion of antibiotic use based on the WHO AWaRe classification in tertiary and secondary level hospitals in Bangladesh. A point prevalence survey (PPS) was conducted adapting the WHO PPS design in inpatients departments in 2021. Among the 1417 enrolled patients, 52% were female and 63% were from the 15-64 years age group. Nearly 78% of patients received at least one antibiotic during the survey period. Third-generation cephalosporins (44.6%), penicillins (12.3%), imidazoles (11.8%), aminoglycosides (7.2%), and macrolides (5.8%) were documented as highly used antibiotics. Overall, 64.0% of Watch, 35.6% of Access, and 0.1% of Reserve group antibiotics were used for treatment. The use of Watch group antibiotics was high in medicine wards (78.7%) and overall high use of Watch antibiotics was observed at secondary hospitals (71.5%) compared to tertiary hospitals (60.2%) (p-value of 0.000). Our PPS findings underscore the need for an urgent nationwide antibiotic stewardship program for physicians including the development and implementation of local guidelines and in-service training on antibiotic use.Entities:
Keywords: AWaRe; Bangladesh; WHO; access; antibiotics; hospitals; watch
Year: 2022 PMID: 35740216 PMCID: PMC9220119 DOI: 10.3390/antibiotics11060810
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Demographic and clinical characteristics of the patients enrolled in the point prevalence survey of antimicrobial usage at tertiary and secondary level hospitals in Bangladesh from February to April 2021.
| Characteristics | Tertiary Level Hospitals (N = 892) | Secondary Level Hospitals (N = 525) | Overall (N = 1417) |
|---|---|---|---|
|
| |||
| Female | 455 (51.0) | 276 (52.6) | 731 (51.6) |
| Male | 437 (48.9) | 249 (47.43) | 686 (48.4) |
|
| |||
| 0–14 years age group | 251 (28.1) | 148 (28.2) | 399 (28.2) |
| 15–64 years age group | 561 (62.9) | 326 (62.1) | 887 (62.6) |
| 65 years and above | 80 (9.0) | 51 (9.7) | 131 (9.2) |
|
| 31.2 (23.1) | 30.9 (23.5) | 31.1 (23.3) |
|
| |||
| No education | 453 (50.8) | 270 (51.4) | 723 (51.0) |
| Primary | 181 (20.3) | 80 (15.2) | 261 (18.4) |
| Secondary | 176 (19.7) | 116 (22.1) | 292 (20.6) |
| Higher | 82 (9.2) | 59 (11.2) | 141 (10.0) |
| Patient transfer from another hospital | 218 (24.4) | 39 (7.4) | 257 (18.1) |
| Patient hospitalized in last 3 months | 138 (15.5) | 63 (12.0) | 201 (14.2) |
|
| |||
| Central vascular catheter | 11 (1.2) | 4 (1.0) | 15 (1.1) |
| Peripheral vascular catheter | 649 (73.0) | 398 (75.8) | 1047 (73.9) |
| Urinary catheter | 103 (11.6) | 27 (5.1) | 130 (9.2) |
| Intubation tube | 4 (0.5) | 1 (0.2) | 5 (0.4) |
| Had surgery after admission | 165 (18.5) | 57 (10.9) | 222 (15.7) |
| Patients on antimicrobials | 716 (80.3) | 441 (84.0) | 1157 (81.7) |
| Patients on antibiotics | 669 (75.0) | 430 (81.9) | 1099 (77.6) |
| Average number of antimicrobials used among patients since admission | |||
| Mean (±SD) | 1.9 (±1.06) | 1.6 (±0.80) | 1.8 (±0.98) |
| Average number of antibiotics used among patients since admission | |||
| Mean (±SD) | 1.3 (±1.56) | 1.2 (±0.46) | 1.2 (±0.53) |
| Medical prophylaxis | 317 (44.3) | 235 (53.3) | 552 (47.7) |
| Community-acquired infection | 234 (32.7) | 134 (30.4) | 368 (31.8) |
| Hospital-acquired infection | 5 (0.7) | 4 (0.9) | 9 (0.8) |
| Surgical prophylaxis | 191 (26.7) | 73 (16.6) | 264 (22.8) |
|
| |||
| One dose on 1 day/multiple days (SP1) | 5 (2.6) | 2 (2.7) | 7 (2.7) |
| Multiple doses on 1 day (SP2) | 3 (1.6) | 9 (12.3) | 12 (4.6) |
| Multiple doses > 1 day (SP3) | 183 (95.8) | 62 (84.9) | 245 (92.8) |
SD—Standard deviation; SP—Surgical Prophylaxis.
Use of antibiotics according to demographic and clinical characteristics of enrolled patients at tertiary and secondary level hospitals in Bangladesh from February to April 2021.
| Characteristics | Antibiotic Use in Tertiary Level Hospitals (N = 892) | Antibiotic Use in Secondary Level Hospitals (N = 525) | Overall Antibiotic Use (N = 1417) | |
|---|---|---|---|---|
|
| ||||
| Female | 338 (74.3) | 227 (82.3) | 0.013 | 565 (77.3) |
| Male | 331 (75.7) | 203 (81.5) | 0.080 | 534 (77.8) |
|
| ||||
| 0–14 years | 214 (85.3) | 145 (98.0) | 0.000 | 359 (90.0) |
| 15–64 years | 407 (72.6) | 248 (76.1) | 0.249 | 655 (73.8) |
| 65 years and above | 48 (60.0) | 37 (72.6) | 0.142 | 85 (64.9) |
|
| ||||
| Medicine | 168 (62.5) | 145 (71.1) | 0.050 | 313 (66.2) |
| Surgery | 189 (75.0) | 123 (83.1) | 0.059 | 312 (78.0) |
| Gynae and Obstetrics | 118 (78.7) | 66 (86.8) | 0.136 | 184 (81.4) |
| Pediatrics | 194 (87.8) | 96 (99.0) | 0.001 | 290 (91.2) |
|
| 161 (97.6) | 57 (100.0) | 0.236 | 218 (98.2) |
|
| ||||
| Peripheral vascular catheter | 545 (84.0) | 340 (85.4) | 0.528 | 885 (84.5) |
| Urinary catheter | 90 (87.4) | 23 (85.2) | 0.763 | 113 (86.9) |
| Central vascular catheter | 7 (63.6) | 4 (100.0) | 0.159 | 11 (73.3) |
| Intubation device | 4 (100.0) | 0 (0.0) | 0.025 | 4 (80.0) |
|
| ||||
| Patients transferred from another hospital | 180 (82.6) | 35 (89.7) | 0.264 | 215 (83.7) |
| Hospitalization within the last 90 days | 97 (70.3) | 47 (74.6) | 0.529 | 144 (71.6) |
|
| ||||
| Medical Prophylaxis | 293 (92.4) | 223 (94.9) | 0.246 | 516 (93.5) |
| Community-Acquired Infections | 213 (91.0) | 130 (97.0) | 0.028 | 343 (93.2) |
| Surgical Prophylaxis | 189 (99.0) | 73 (100.0) | 0.380 | 262 (99.2) |
| Hospital-Acquired Infections | 5 (100.0) | 4 (100.0) | 9 (100.0) |
* Denominators are taken from Table 1.
Distribution of antimicrobial use according to different departments and types of hospitals in Bangladesh from February to April 2021.
| Antimicrobials Used | WHO AWaRe Classification | Number of Antimicrobial Agents Used According to Different Departments | Number of Antimicrobial Agents Used According to the Types of Hospitals | Overall Antimicrobial Agents Used (N = 2138) | ||||
|---|---|---|---|---|---|---|---|---|
| Medicine | Surgery | Gynae and Obstetrics | Pediatrics | Tertiary Level Hospitals | Secondary Level Hospitals | |||
| Antibiotics (In total) | 455 (98.3) | 607 (99.3) | 478 (99.8) | 572 (97.8) | 1397 (98.7) | 715 (99.0) | 2112 (98.8) | |
| Cephalosporins Group (In total) | 241 (52.1) | 347 (56.8) | 213 (44.5) | 285 (48.7) | 693 (48.9) | 393 (54.4) | 1086 (51.4) | |
| 1st-generation cephalosporins | Access | 0 (0.0) | 0 (0.0) | 23 (4.8) | 0 (0.0) | 23 (1.6) | 0 (0.0) | 23 (1.1) |
| 2nd-geneneration cephalosporins | Watch | 22 (4.8) | 37 (6.1) | 31 (6.5) | 3 (0.5) | 45 (3.2) | 48 (6.6) | 93 (4.3) |
| 3rd-geneneration cephalosporins | Watch | 217 (46.9) | 304 (49.8) | 158 (33.0) | 275 (47.0) | 622 (43.9) | 332 (46.0) | 954 (44.6) |
| 4th-geneneration cephalosporins | Watch | 2 (0.4) | 4 (0.7) | 1 (0.2) | 7 (1.2) | 2 (0.1) | 12 (1.7) | 14 (0.7) |
| 2nd-geneneration cephalosporins + beta lactamase inhibitors | Not recommended | 0 (0.0) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 1 (0.1) | 2 (0.1) |
| Imidazoles | Access | 34 (7.3) | 86 (14.1) | 121 (25.3) | 12 (2.1) | 172 (12.1) | 81 (11.2) | 253 (11.8) |
| Penicillins | Access | 11 (2.4) | 116 (19.0) | 56 (11.7) | 80 (13.7) | 167 (11.8) | 96 (13.3) | 263 (12.3) |
| Aminoglycosides | Access | 2 (0.4) | 13 (2.1) | 7 (1.5) | 132 (22.6) | 137 (9.7) | 17 (2.4) | 154 (7.2) |
| Macrolides | Watch | 82 (17.7) | 3 (0.5) | 31 (6.5) | 8 (1.4) | 60 (4.2) | 64 (8.9) | 124 (5.8) |
| Fluoroquinolones | Watch | 25 (5.4) | 23 (3.8) | 40 (8.4) | 8 (1.4) | 53 (3.7) | 43 (6.0) | 96 (4.5) |
| Carbapenems | Watch | 9 (1.9) | 10 (1.6) | 4 (0.8) | 41 (7.0) | 52 (3.7) | 12 (1.7) | 64 (3.0) |
| Beta lactam-beta lactamase inhibitors | Access | 41 (8.9) | 2 (0.3) | 1 (0.2) | 1 (0.2) | 42 (3.0) | 3 (0.4) | 45 (2.1) |
| Glycopeptides | Watch | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (0.9) | 5 (0.4) | 0 (0.0) | 5 (0.2) |
| Lincosamide | Access | 2 (0.4) | 3 (0.5) | 4 (0.8) | 0 (0.0) | 5 (0.4) | 4 (0.6) | 9 (0.4) |
| Furadantin | Access | 3 (0.6) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 3 (0.2) | 1 (0.1) | 4 (0.2) |
| Anti-tubercular agents | Not- classified | 3 (0.6) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 4 (0.3) | 0 (0.0) | 4 (0.2) |
| Rifamycins | Watch | 1 (0.2) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (0.1) | 0 (0.0) | 2 (0.1) |
| Oxazolidinones | Reserve | 0 (0.0) | 1 (0.2) | 1 (0.2) | 0 (0.0) | 1 (0.1) | 1 (0.1) | 2 (0.1) |
| Trimethoprim-sulfonamide combinations | Access | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 1 (0.0) |
| Antivirals | Non-Antibiotics | 6 (1.3) | 2 (0.3) | 1 (0.2) | 10 (1.7) | 15 (1.1) | 4 (0.6) | 19 (0.9) |
| Antifungals | Non-Antibiotics | 0 (0.0) | 1 (0.2) | 0 (0.0) | 1 (0.2) | 2 (0.1) | 0 (0.0) | 2 (0.1) |
| Antiparasitics | Non-Antibiotics | 2 (0.4) | 0 (0.2) | 0 (0.0) | 2 (0.3) | 1 (0.1) | 3 (0.4) | 5 (0.2) |
| Total | 463 (100.0) | 611 (100.0) | 479 (100.0) | 585 (100.0) | 1416 (100.0) | 722 (100.0) | 2138 (100.0) | |
Figure 1Number of antibacterial agents used for treating patients during hospitalization on the day of the point prevalence survey at different departments of tertiary and secondary level hospitals in Bangladesh from February to April 2021.
Figure 2Antibiotics usage according to the WHO AWaRe classification at different departments of tertiary and secondary level hospitals in Bangladesh from February to April 2021.
Figure 3(A,B): Multivariate logistic regression model for the association between Access and Watch-group antibiotics and baseline covariates at tertiary and secondary level hospitals in Bangladesh from February to April 2021.